Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome

@article{Keating2013EculizumabAR,
  title={Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome},
  author={Gillian M. Keating},
  journal={Drugs},
  year={2013},
  volume={73},
  pages={2053-2066}
}
The recombinant humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome (aHUS). This article reviews the clinical efficacy and tolerability of eculizumab in the treatment of patients with aHUS, as well as summarizing its pharmacological properties. Intravenous eculizumab inhibited complement-mediated thrombotic microangiopathy in patients aged ≥12 years with aHUS, according to the results of… Expand
Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome
TLDR
In conclusion, eculizumab is a valuable new agent for use in the treatment of aHUS and the proportion of patients meeting criteria for improvement in renal function increased over 2 years of therapy. Expand
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
TLDR
A 2-year analysis found that the earlier clinical benefits achieved by eculizumab treatment of aHUS were maintained at 2 years of follow-up. Expand
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
TLDR
The currently available evidence suggests TMA manifestations following discontinuation are unpredictable in both severity and timing, and better risk stratification and valid monitoring strategies are required for evidence-based decision making. Expand
Eculizumab: A Review in Generalized Myasthenia Gravis
TLDR
Although several questions remain, such as duration of treatment, cost effectiveness and long-term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gMG. Expand
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
TLDR
The beneficial effect of eculizumab was seen across all patient subgroups analysed and was accompanied by improvements in neurological and functional disability assessments, as well as generic health-related quality of life measures; it was sustained through 4 years of treatment. Expand
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
TLDR
Younger age, higher baseline LDH and lower baseline hemoglobin were associated with greater eGFR improvements, demonstrating the importance of rapid diagnosis and treatment of patients with aHUS. Expand
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumabExpand
Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
TLDR
A case of a patient with human immunodeficiency virus infection who developed TMA and was successfully treated with eculizumab is presented, and the effect of long-term treatment with this new medication is unknown. Expand
Atypical hemolytic uremic syndrome: from diagnosis to treatment
  • M. Franchini
  • Medicine
  • Clinical chemistry and laboratory medicine
  • 2015
TLDR
For the management of TTP, plasma exchange (PE) is the most important acute intervention and is associated with lower mortality and better outcomes than plasma infusion, and eculizumab has been approved as first-line therapy when an unequivocal diagnosis of aHUS has been made. Expand
Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group
TLDR
This document pretends to summarise the current status of knowledge of the pathophysiology of TMA and the therapeutic options available, and to offer a diagnostic and therapeutic practical tool to the professionals caring for the patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
TLDR
A number of important issues require further study, including the appropriate duration of treatment according to an individual's genetic background and medical history, the optimal strategy to prevent post-transplantation recurrence of aHUS and a cost–efficacy analysis. Expand
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
TLDR
Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome and was also associated with improvement in health-related quality of life. Expand
Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
TLDR
Eculizumab, the first targeted terminal complement inhibitor, provides an effective and generally well tolerated treatment for PNH patients, who have previously been without adequate treatment options. Expand
Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
TLDR
Information from case series and prospective studies indicate that eculizumab use has dramatically improved the renal prognosis of aHUS, and prompted the French working group on aH US to propose a new algorithm for the management of a HUS in children and in adults. Expand
Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
TLDR
Chronic eculizumab treatment was associated with control of complement-mediated TMA and sustained long-term improvement in renal and cardiac function. Expand
Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)
TLDR
This trial confirms that Ecu inhibits complement-mediated TMA, and is safe and effective as first-line therapy at the approved dose regimen in pediatric pts with aHUS. Expand
Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome
TLDR
Eculizumab, a monoclonal antibody that targets complement factor C5, blocks activation of the terminal complement cascade and the generation of the proinflammatory and prothrombotic molecules C5a and C5b-9. Expand
Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis.
TLDR
This case illustrates the difficulty but importance of early consideration of aHUS in patients presenting with TMA and highlights that near-normal renal recovery may be attained with eculizumab in adults even after a long dependence on dialysis. Expand
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
TLDR
Eculizumab has a substantial impact on the symptoms and complications of PNH and results a significant improvement in patient survival, with no evidence of cumulative toxicity and a decreasing occurrence of adverse events over time. Expand
Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
TLDR
It is demonstrated that platelet count is not always a reliable marker for improvement of aHUS and that eculizumab can prevent dialysis in plasma-resistant aH US patients. Expand
...
1
2
3
4
5
...